Verrica Pharmaceuticals (VRCA) Q4 2025 earnings summary

Executive summary

• Achieved significant transformation in 2025, doubling core product revenue and reducing costs, while advancing clinical and commercial initiatives.

• Total revenue for 2025 rose to $35.6 million, a 370% increase year-over-year, driven by YCANTH and milestone payments.

• YCANTH net revenue grew 130% to $15.3 million in 2025, with applicator units dispensed nearly doubling.

• Selling, general, and administrative expenses decreased by over 40% year-over-year, reflecting operational efficiencies.

• No outstanding debt as of year-end 2025; cash runway extended into Q1 2027.

Financial highlights

• Q4 2025 revenue was $5.1M, up from $0.3M in Q4 2024; full-year 2025 revenue reached $35.6M, a 368% increase year-over-year.

• Net YCANTH revenue for 2025 was $15.3M, with $20.3M from Torii milestone and collaboration revenue.

• Gross product margin improved to 85.7% for 2025, up from 71.8% in 2024.

• GAAP net loss for 2025 was $17.9M ($1.68/share), significantly reduced from $76.6M ($14.78/share) in 2024.

• Cash and equivalents at year-end 2025 were $30.1M, expected to fund operations into 2027.

Outlook and guidance

• Anticipates continued growth in YCANTH utilization, with expanded sales force and new access initiatives.

• Expects to file for EU approval of YCANTH within 12 months, targeting commercialization partnerships.

• Ongoing phase III trials for common warts and preparation for phase III in basal cell carcinoma, with updates on timelines expected later in 2026.

• No formal 2026 revenue guidance provided, but management expresses optimism based on early Q1 momentum.

• Regulatory alignment in the EU allows for YCANTH approval filing without additional clinical studies.